Easing the Economic and Clinical Burden of Psoriasis and Psoriatic Arthritis: The Role of Managed Care

In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and adolescents with moderate to severe plaque psoriasis.

August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals with diverse skin tones.

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council guidelines.

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.